Vitals
“I’m here to check your vitals – Instagram, Twitter and Facebook pages.”
Read More
Author: Teresa Sellinger
Q&A: Availability of Multiple Options for NSCLC is “Very Exciting”
Selecting a treatment for operable non-small cell lung cancer from the many options available involves consideration of tumor stage and biomarkers.
Read More
Primary Care Intervention Aids Patient Follow-Up for Abnormal Cancer Screening
Primary care clinicians take a “whole person” approach and are responsible for a wide range of preventive healthcare efforts.
Read More
Healthcare Organizations Can Do More for Women Leaders in Academic Medicine
Women are underrepresented in leadership positions in a wide range of industries, and medicine is no exception. Healthcare organizations can do more for women.
Read More
Addressing New Challenges in Medical Education
Medical education faces challenges that affect the quality of training and the preparedness of future healthcare workforce.
Read More
In Patients With HIV, Non-Alcoholic Fatty Liver Disease Increases Cardiovascular Risk
Patients with HIV and NAFLD experience a greater risk for adverse cardiovascular outcomes than those with HIV alone.
Read More
Functional MRI Identifies Changes in Cerebral Regional Homogeneity Among Patients With TD
Resting-state functional MRI results show that patients with schizophrenia and tardive dyskinesia have altered cerebral regional homogeneity.
Read More
Selpercatinib Doubles Progression-Free Survival in RET-Mutated NSCLC
Selpercatinib doubled progression-free survival, increased response rate, and delayed pulmonary and physical deterioration in RET fusion-positive NSCLC.
Read More
No Surgery After Neoadjuvant Chemoradiotherapy in Esophageal Cancer?
Active surveillance after neoadjuvant chemoradiotherapy may be an alternative to surgery for some with esophageal cancer.
Read More
Toripalimab/Chemotherapy Combo Improves Outcomes in Small Cell Lung Cancer
Toripalimab added to etoposide plus cisplatin or carboplatin improved survival in extensive-stage small cell lung cancer.
Read More
Addition of Pembrolizumab Improves pCR in Patients With Early-Stage High-Risk ER+/HER2- Breast Cancer
Pembrolizumab plus neoadjuvant chemotherapy in early-stage, high-risk ER+/HER2- breast cancer leads to a statistically significant increase in pathological complete response.
Read More
NICHE-3 Demonstrates Equally Impressive Results as NICHE-2
Nivolumab/relatlimab neoadjuvant treatment of deficient mismatch repair colon cancer shows impressive pathological response rates.
Read More
EV/Pembrolizumab Raises the Bar for OS in Metastatic Urothelial Cancer
First-line enfortumab vedotin (EV) plus pembrolizumab significantly improved survival in patients with locally advanced or metastatic urothelial cancer.
Read More
Is There Space for Physicians and Nurses to Both Claim ‘Doctor’?
The healthcare arena’s figurative boxing match between physicians and nurses over who besides...
Read More
Lifileucel Induces Durable Response in Heavily Pretreated Mucosal Melanoma
One-time lifileucel induces a strong and durable response in patients with advanced mucosal melanoma.
Read More
Perioperative Nivolumab Boosts Event-Free Survival in NSCLC
Perioperative chemotherapy plus nivolumab outperforms perioperative chemotherapy alone in patients with resectable non-small cell lung cancer.
Read More
LuPSMA & Enzalutamide: A Promising Combination
Enzalutamide plus LuPSMA has enhanced anticancer effects in prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.
Read More
Most Infants in ICU for RSV in 2022 Were Otherwise Healthy
Most infants admitted to the ICU with RSV do not have an underlying medical condition, but RSV remains a top cause of hospitalization in the first year of life.
Read More
Generative AI Poised to Revolutionize Healthcare Delivery & Life Sciences Research
Generative AI technology may transform healthcare delivery and life sciences productivity by improving patient outcomes and increasing clinical and medical research efficiency.
Read More
Durvalumab Climbs the MATTERHORN of Gastric Cancer
Durvalumab added to chemotherapy improves pathological complete response rate in the perioperative setting for patients with gastric cancer.
Read More